-
Wednesday, March 30, 2011 - 12:25pm
Cephalon Stocks Surge After Valeant Makes Bid Public (CEPH, VRX)
Cephalon (NASDAQ: CEPH) stock rose $16.45 this morning, stopping at $75.20 a share after a hostile takeover bid of approximately $5.7 billion from Valeant Pharmaceuticals International (NYSE: VRX). Cephalon's surge is Nasdaq's biggest intraday gain since April 2000. Cephalon's surge of...
Read More >> -
Cowen & Co Upgrades SVNT To Outperform
Thursday, October 28, 2010 - 7:33amAnalysts at Cowen & Co upgrade Savient Pharmaceuticals Inc (NASDAQ: SVNT) from "neutral" to "outperform." The target price for SVNT is set to $19. SVNT's shares gained 10.08% to close at $12.67 yesterday. More Analyst Ratings here
Read More >> -
Cowen & Co Upgrades GR To Outperform
Friday, October 22, 2010 - 7:55amAnalysts at Cowen & Co upgrade Goodrich Corporation (NYSE: GR) from "neutral" to "outperform." GR's shares gained 1.89% to close at $79.34 yesterday. More Analyst Ratings here
Read More >> -
Cowen & Co Upgrades ANN To Neutral
Thursday, October 7, 2010 - 8:15amAnalysts at Cowen & Co upgrade AnnTaylor Stores Corp (NYSE: ANN) from "underperform" to "neutral." ANN's shares lost 1.48% to close at $20.58 yesterday. More Analyst Ratings here
Read More >> -
Market Roundup (GENZ, SNY, BP, C, BAC, MOT, AAPL, KO)
Monday, July 26, 2010 - 3:27pmBloomberg has quoted unidentified sources as saying that Genzyme (NASDAQ: GENZ) has refused the takeover offer from Sanofi-Aventis (NYSE: SNY). GENZ is, maybe, holding out for a better offer. Analyst Phil Nadeau of Cowen & Co said that it is just a matter of time, “given that Genzyme has...
Read More >> -
ISIS Collaboration With GlaxoSmithKline Not Favorable
Wednesday, March 31, 2010 - 3:25pmAnalysts at Cowen & Co maintain their "neutral" rating on Isis Pharmaceuticals (NASDAQ: ISIS). Isis and GlaxoSmithKline (NYSE: GSK) have collaborated as a result of which ISIS will develop a maximum of six antisense candidates for rare and serious diseases. Cowen & Co does not consider the...
Read More >> -
SYNA Downgraded On Slower Growth In Handset Segment
Tuesday, March 30, 2010 - 10:47amAnalysts at Cowen & Co downgrade Synaptics (NASDAQ: SYNA) from "outperform" to "neutral," while lowering their estimates for the company. According to Cowen & Co, the downgrade in the rating is based on slower growth in the handset segment. The analysts expect Synaptics to maintain its...
Read More >> -
UTHR Posts Strong Q4 Revenues, As Well As Expenses
Tuesday, February 16, 2010 - 2:37pmAnalysts at Cowen & Co maintain their "outperform" rating on United Therapeutics (NASDAQ: UTHR). United Therapeutics reported Q4 revenues ahead of expectations, driven by strong Tyvaso revenues. Earnings missed expectations due to higher SG&A and R&D expenses, the analysts say. “We...
Read More >> -
GILD Reports Solid Numerical Data For Quad Combo Pill
Tuesday, February 16, 2010 - 2:35pmAnalysts at Cowen & Co maintain their "outperform" rating on Gilead Sciences Inc (NASDAQ: GILD). Numerical data from the Phase II proof-of-concept studies of Gilead Sciences’ Quad Combo pill and GS9350, GILD’s proprietary PK booster, were solid. The results “provide us with increased confidence...
Read More >> -
Termination Of Constellation Program To Affect ATK Sales In H2 2011
Tuesday, February 2, 2010 - 2:12pmAnalysts at Cowen & Co maintain their "neutral" rating on Alliant Techsystems (NYSE: ATK). Cowen & Co believes that the consensus revenues and EPS for Alliant Techsystems will be lowered for 2H10, as NASA’s F11 budget request seeks to terminate the “Constellation” program and retire the...
Read More >>
